Mitsui Chemicals, Inc.
4183・Prime Market・Chemicals
Life & Healthcare Solutions
Mitsui Chemicals' high-profitability growth segment addressing QOL improvement and health challenges
| Period | Current | Previous | Change |
|---|---|---|---|
| Revenue (external customers) | ¥259,076 million | ¥251,677 million | ↑ |
| Core operating income | ¥34,188 million | ¥34,041 million | ↑ |
| Segment assets | ¥408,756 million | ¥395,224 million | ↑ |
| Depreciation and amortization | ¥18,417 million | ¥16,962 million | ↑ |
| Capital expenditures | ¥40,030 million | ¥26,372 million | ↑ |
| Share of profit of investments accounted for using the equity method | ¥1,243 million | ¥846 million | ↑ |
| Impairment loss | ¥8,306 million | ¥8,771 million | ↓ |
| Revenue (total segment) | ¥264,258 million | ¥254,960 million | ↑ |
Business Details
A segment centered on Vision Care Materials (eyeglass lens materials), Oral Care Materials (dental materials), Personal Care Materials, and Agrochemicals & Environmental Health Chemicals. Against the backdrop of declining birthrates and aging populations in developed countries and population growth in emerging countries, the segment addresses quality-of-life improvement and food resource challenges. Accounts for 15% of total revenue (FY2026, ending March 2026). Main affiliated companies include Kulzer GmbH and Mitsui Chemicals Crop & Life Solutions, Inc.
Recent Overview
Vision Care and agrochemicals remained solid, absorbing the impact of the Omuta plant suspension to achieve higher revenue and profit
In FY2026 (ending March 2026), revenue increased to ¥264,258 million (up ¥7.4 billion year on year) and core operating income increased to ¥34,188 million (up ¥0.1 billion year on year), representing higher revenue and profit. Sales of Vision Care eyeglass lens materials trended solidly, while fixed costs deteriorated due to the impact of the suspension of manufacturing equipment at the Omuta plant. Agrochemical sales were solid. Oral care sales were in line with the prior period, but fixed costs improved due to business structure improvements. The tender offer for DNA Chip Research Inc. was completed, making it a wholly owned subsidiary. SDC Technologies, Inc. relocated its headquarters in the US and substantially strengthened its R&D and manufacturing functions. The forecast for FY2027 (ending March 2027) is core operating income of ¥38,000 million (up ¥3.8 billion year on year).
Key Products
Growth Drivers
- Expanding QOL improvement needs against the backdrop of global aging populations and population growth
- Increasing demand for high-refractive-index lenses in Vision Care Materials (Europe, US, China, India)
- Expansion of the high-performance coating materials business through strengthened R&D and manufacturing functions at SDC Technologies, Inc.
- Sales promotion and new product registration advancement for agrochemicals in key overseas countries (such as Africa)
- The trend of material shift from metal to resin in dental materials and strengthened profitability at Kulzer (fixed cost improvement through business structure improvements)
- Nurturing a third pillar of earnings in the medical field (genetic diagnostics and contract services) through the full consolidation of DNA Chip Research Inc.
Risks
- Risk of continued fixed cost deterioration due to the suspension of manufacturing equipment at the Omuta plant
- Risk of delayed improvement in profitability at Kulzer GmbH (challenges include strengthening marketing/sales functions and improving cost structure)
- Supply chain concentration risk in agrochemicals (need to strengthen active ingredient production systems at the Omuta and Kitakami plants)
- Foreign exchange risk (high proportion of overseas sales; revenue and profit are pressured when the yen appreciates)
- Risk of intensified market entry and price competition in the high-refractive-index lens material market by competitors
- Risk of upfront investment burden associated with nurturing the medical field business (DNA Chip Research Inc.)
Last updated: June 22, 2026